The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis

TELO-SCOPE

TELO-SCOPE is a national, multi-centre, double-blind, placebo-controlled, randomised (2:1) trial which will test the hypothesis that, compared to placebo, the addition of danazol to standard of care in pulmonary fibrosis associated with short telomeres is safe and will result in reduced telomere attrition.

2021-09-07

2024-12-01

2025-06-01

Recruiting

Early phase I

50

Inclusion Criteria: 1. Males and females aged \>5 years, able to take capsules orally. 2. Fibrosing interstitial pneumonia (Idiopathic PF, idiopathic non-specific interstitial pneumonia, chronic hypersensitivity pneumonitis, pleuroparenchymal fibroelastosis, unclassifiable interstitial lung disease (ILD)) diagnosed according to the current international guidelines. 3. Age-adjusted peripheral blood leukocyte telomere length \< 10th centile on Flow-FISH. 4. FVC \> 40% predicted. 5. DLCO \> 25% predicted. 6. If receiving background pirfenidone / nintedanib, stable dose for 28 days prior to screening. 7. Able to understand and sign a written informed consent form (or legally authorised representative). 8. Agreement to use a medically approved form of non-hormonal contraception (if of child-bearing potential) (noting that oral contraceptives are advised not to be used concurrently with danazol). Exclusion Criteria: 1. Actively or imminently listed for lung transplantation. 2. Undergone, awaiting, or likely to require bone marrow transplantation within 12 months. 3. Concurrent enrolment in another study. 4. Females with a positive pregnancy test at screening or currently breastfeeding. 5. Pelvic infection. 6. Past jaundice with oral contraceptives. 7. Undiagnosed abnormal genital bleeding. 8. Undiagnosed ovarian/uterine masses 9. Any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 12 months. 10. History of androgen-dependent tumour. 11. Any condition other than PF that, in the opinion of the investigator, is likely to result in the death of the participant within the next 12 months. 12. History of end-stage liver disease or ALT or AST \> 3 times the upper limit of normal. 13. History of end-stage kidney disease requiring dialysis. 14. Markedly impaired cardiac function. 15. Known increased risk of or history of thromboembolism (e.g. Factor V Leiden, Protein C or S deficiency). 16. Uncontrolled hypertension. 17. Uncontrolled lipoprotein disorder. 18. Poorly-controlled diabetes mellitus. 19. History of marked or persistent androgenic reaction to previous gonadal steroid therapy. 20. History of epilepsy induced or worsened by previous gonadal steroid therapy. 21. History of raised intracranial pressure. 22. Known intolerance to danazol. 23. Porphyria. 24. Use of any of the following agents within 28 days before screening: danazol or other androgen therapy, warfarin or other anticoagulant, carbamazepine, phenytoin, investigational therapy, cytotoxic therapy, tacrolimus, cyclosporine. 25. Professional singer due to potential for voice change. 26. Competitive athletes. 27. Prostate specific antigen (PSA) above the upper limit of normal (adult males only).

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}}

2024-01-23